The expansion covers Australia, New Zealand, South Korea, and Taiwan, with a combined population of approximately 100 million people. In all of these new markets, Karo Healthcare is the market leader in antifungal foot treatments with the Lamisil brand through athlete’s foot products, and the intention is to broaden the portfolio with Moberg Pharma’s nail fungus treatment under the same established brand.

The financial terms are not disclosed, but the agreement includes royalty revenues and compensation for delivered products. The next step is a regulatory process in which the companies, based on the European registration file and supplemented with additional data to meet local regulatory requirements, intend to apply for marketing approval with the relevant regulatory authorities in each country.

“The agreement represents the next step in our geographic expansion. Karo Healthcare is the market leader in antifungal foot treatments with Lamisil across all of these markets, providing a strong foundation for a successful launch of
MOB-015,” says Anna Ljung, CEO of Moberg Pharma.

“We are pleased to expand our collaboration with Moberg Pharma. MOB-015 is a clinically well-documented product and fits well with our strategy to further develop the Lamisil brand. The collaboration represents a strong combination of scientific innovation and commercial strength, giving us a unique position in the market,” says Michael Kaltenborn, Chief Strategy and Corporate Development Officer at Karo.